* Rhythm Pharmaceuticals Inc RYTM.OQ reported a quarterly
adjusted loss of 69 cents per share for the quarter ended in
June, higher than the same quarter last year, when the company
reported EPS of -82 cents. The mean expectation of
nine analysts for the quarter was for a loss of 71 cents per
share. Wall Street expected results to range from -80 cents
to -60 cents per share.
* Revenue rose 51.3% to $29.08 million from a year ago;
analysts
expected $28.79 million.
* Rhythm Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 55 cents.
* The company reported quarterly net income of $33.57
million.
* Rhythm Pharmaceuticals Inc shares had risen by 7.2% this
quarter and lost 4.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.
* In the last 30 days, two analysts negatively revised
earnings
estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Rhythm
Pharmaceuticals Inc is $55.00
This summary was machine generated from LSEG data August 6 at
01:31 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.71 -0.69 Beat
Mar. 31 2024 -2.16 -2.35 Missed
Dec. 31 2023 -0.70 -0.70 Met
Sep. 30 2023 -0.74 -0.76 Missed